HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $65
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $50 to $65.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $50 to $65.